+1-888-308-5802     
News Contact Us

ICC secures master license for cannabinoid extraction technology

Author : Pankaj Singh | Published Date : 2019-05-28 

ICC has plans to combine the Affinity Unit into its vertically integrated cannabis asset range covering 20 nations around 4 continents.

ICC International Cannabis Corp. has reportedly announced that it has secured the exclusive European master license to the Affinity Alpha Unit, an innovative cannabinoid extraction system. The Affinity Unit uses a two-phase extraction process to facilitate the mass production of highly purified CBG, CBD, THC and terpene extracts at 10 times the throughput of conventional extraction technologies.

Reportedly, the Affinity Unit uses advanced processing nanotechnologies and proprietary and patented molecular imprinting to provide near-quantitative levels of purity, improved durability, nil production bottlenecks, product uniformity and predictability, and continuous process flow.

ICC has plans to combine the Affinity Unit into its vertically integrated cannabis asset range covering 20 nations around 4 continents. This will result in optimized manufacturing efficacy of its form factors and proprietary formulations.

Apparently, ICC will leverage the Affinity Unit to accelerate post-harvest production of finished goods from its standing extraction-ready CBD inventories in Switzerland, Germany, Croatia and Serbia.

David Shpilt, Chief Executive Officer, International Cannabis, reportedly stated that the integration of the Affinity Unit across global operating units of ICC will optimize its multi-pronged CBD strategy, consequently maximizing rents while concerning high growth consumer segments. A patented two-phase extraction method, supplied with 10 times the conventional industry output will allow ICC to bring its high-class product formulations to market at an expedited rate, further representing its first mover reputation across the EU, he further added.

Under the terms of ROFR, the first-in-line option has been granted to ICC to buy the exclusive master licensing rights for the deployment and use of the Affinity Technology across the Dependent Territories of Europe and Sovereign States.

Additionally, ICC plans to invest $1,500,000 in Atom at an issue price of $0.75 per share, to shut on or before May 31, 2019.

Source credit: https://www.globenewswire.com/news-release/2019/05/27/1850098/0/en/International-Cannabis-Secures-Exclusive-Master-License-for-Revolutionary-Cannabinoid-Extraction-Technology-to-Integrate-Across-the-EU-and-India.html

https://markets.businessinsider.com/news/stocks/international-cannabis-secures-exclusive-master-license-for-revolutionary-cannabinoid-extraction-technology-to-integrate-across-the-eu-and-india-1028231497

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Sir Richard Branson to contribute £200M to stabilize Virgin Atlantic

Published Date: 2020-07-14         Author: Pankaj Singh

British business magnate Sir Richard Branson had reportedly announced that he intends to contribute a sum of £200 million as part of the £1 billion plan to stabilize Virgin Atlantic without taxpayers’ money. Sources state that he will use the funds raised by selling a £396 mi... Read More

The Electric Cycle Company announces plans to move to bigger premises

Published Date: 2020-07-13         Author: Pankaj Singh

After a successful launch of a £70,000 crowdfunding campaign to renovate its shop and workshop, the Scottish e-bike firm Electric Cycle Company has reportedly announced its plans to move to a 4000 sq. ft., carbon-neutral Edinburgh-based premise, which will be the largest e-bike shop in the UK.... Read More

Cipla launches generic version of Remdesivir at a price of ₹4,000

Published Date: 2020-07-10         Author: Pankaj Singh

Cipla Limited, the multinational pharmaceutical company, has reportedly launched a generic version of the remdesivir drug (Cipremi) at a price of ?4,000 per 100 mg vial, making it among the least priced COVID-19 treatment available across the globe. According to sources familiar with the knowledg... Read More

© 2020 Fractovia. All Rights Reserved